Eli Lilly and Company (LLY)
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap of around $800 billion.
Eli Lilly: Why Orforglipron Matters, A Lot
Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised)
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Eli Lilly Stock Moves Lower on Rare Double Downgrade
Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150.
Ahead of Lilly (LLY) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings?
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
How Eli Lilly and Novo Nordisk have separated themselves from their rivals
Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the pharmaceutical stocks he covers.
Eli Lilly Will Be the Next $1 Trillion Stock
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.
Eli Lilly: Positioned For Robust Q1 As Orforglipron Enhances Long-Term Outlook
Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds, Lilly's strong pipeline and market leadership in incretin analogues support a "Buy" rating for long-term investors with DCA strategy. Lilly's oncology and neuroscience sectors are progressing, with significant investments in U.S. manufacturing to mitigate potential Pharma Tariffs impact.
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Eli Lilly Stock Going to $900? 1 Wall Street Analyst Thinks So.
Rather counterintuitively, following some promising news about a pipeline drug, one analyst tracking Eli Lilly (LLY 1.21%) stock cut his price target on the pharmaceutical giant. Even though that reduction was substantial, the pundit still sees value in the stock.
Eli Lilly sues four telehealth sites selling compounded Zepbound, Mounjaro
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro. Lilly claims Mochi Health, Fella Health, Willow Health and Henry Meds are deceiving consumers and turning them away from Lilly's medicines.
